TRVN trevena.com: Company Value to Revenue Ratio

Official company branding of Trevena (TRVN)

Challenges in bringing new analgesics to market are putting pressure on the business of Trevena, Inc. (TRVN). Bankruptcy risks and the slow rollout of Olinvyk are complicating the company's financial position. The EV/Sales multiple reflects capitalization dynamics relative to revenue, with the current metric standing at . Simultaneously, Trevena, Inc. (TRVN) is implementing ESG standards by transitioning to eco-friendly packaging and closed-loop water systems at its plants.

Trevena, Inc. (TRVN) Company Value to Revenue: for the period 07/04/2022 - 11/20/2026

TRVN (Trevena, Inc): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental valuation:trevena.com - TRVN
Manufactured products of Trevena Inc.

To isolate the fundamental stability of Trevena, Inc. (TRVN) from market noise, it is necessary to compare the total enterprise value with sales volume, excluding the impact of debt. By analyzing the EV/Sales ratio on the GURU.Markets platform, an investor assesses the efficiency of revenue capitalization, which Trevena, Inc. (TRVN) optimizes through the implementation of automated clinical data processing systems to enhance research accuracy.

Competitor analysis

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|KTTA: Company Value to Revenue|Business Value to Revenue CRGT (cortigent.com)|ATXI: EV/Sales Multiple|BCLI (BrainStorm Cell Therapeutics) - Enterprise Value-to-Revenue Ratio|CARA (Cara Therapeutics Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio CHRO|Company Value to Revenue ELYM (Eliem Therapeutics)|Enterprise Value-to-Revenue Ratio ITCI (Intra-Cellular Therapies Inc.)|EV/Sales Multiple LBPH (Longboard Pharma)|EV/Sales Multiple Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - EV/Sales Multiple|Business Value to Revenue NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Company Value to Revenue|Company Value to Revenue Ratio SNPX|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE